NASDAQ:FBIO Fortress Biotech (FBIO) Stock Price, News & Analysis $2.25 -0.35 (-13.46%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.24▼$2.6050-Day Range$1.67▼$2.6152-Week Range$1.24▼$9.00Volume511,234 shsAverage Volume314,006 shsMarket Capitalization$45.92 millionP/E RatioN/ADividend YieldN/APrice Target$28.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Fortress Biotech alerts: Email Address Fortress Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,166.7% Upside$28.50 Price TargetShort InterestHealthy9.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 6 Articles This WeekInsider TradingAcquiring Shares$128,300 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.07) to ($3.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.59 out of 5 starsMedical Sector284th out of 936 stocksPharmaceutical Preparations Industry130th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFortress Biotech has only been the subject of 3 research reports in the past 90 days.Read more about Fortress Biotech's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.74% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 10.84%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 3.0 News and Social Media Coverage News SentimentFortress Biotech has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search Interest9 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows4 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have bought 578.84% more of their company's stock than they have sold. Specifically, they have bought $128,300.00 in company stock and sold $18,900.00 in company stock.Percentage Held by Insiders33.40% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fortress Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to grow in the coming year, from ($5.07) to ($3.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 22.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Fortress Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Fortress Biotech Stock (NASDAQ:FBIO)Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Read More FBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBIO Stock News HeadlinesJuly 16, 2024 | insidertrades.comLindsay A. Md Rosenwald Acquires 5,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockJuly 2, 2024 | insidertrades.comLindsay A. Md Rosenwald Buys 20,000 Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 8:30 AM | globenewswire.comFortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027July 25 at 7:30 AM | globenewswire.comCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaJuly 24 at 2:06 AM | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Cut to "Sell" at StockNews.comJuly 20, 2024 | americanbankingnews.comFortress Biotech (NASDAQ:FBIO) Receives "Buy" Rating from HC WainwrightJuly 19, 2024 | markets.businessinsider.comFortress Biotech’s Strategic Financial Moves and Clinical Pipeline Promise Bright Revenue Prospects: Pantginis Issues Buy RatingJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 18, 2024 | americanbankingnews.comStockNews.com Upgrades Fortress Biotech (NASDAQ:FBIO) to "Hold"July 16, 2024 | americanbankingnews.comFortress Biotech, Inc. (NASDAQ:FBIO) CEO Lindsay A. Md Rosenwald Acquires 5,000 Shares of StockJuly 15, 2024 | globenewswire.comGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchJuly 11, 2024 | globenewswire.comJourney Medical Corporation Appoints Michael C. Pearce to Board of DirectorsJuly 5, 2024 | globenewswire.comFortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred StockJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJuly 2, 2024 | globenewswire.comCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabJune 24, 2024 | globenewswire.comCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionMay 16, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Fortress Biotech (FBIO), BioLife Solutions (BLFS)See More Headlines Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$28.50 High Stock Price Target$75.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,166.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.0982) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,640,000.00 Net Margins-69.13% Pretax Margin-161.56% Return on EquityN/A Return on Assets-35.47% Debt Debt-to-Equity Ratio38.42 Current Ratio1.33 Quick Ratio1.21 Sales & Book Value Annual Sales$84.51 million Price / Sales0.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book22.50Miscellaneous Outstanding Shares20,410,000Free Float13,594,000Market Cap$45.92 million OptionableOptionable Beta1.74 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman, President & CEO Comp: $942.78kMr. Michael S. Weiss Esq. (Age 58)Vice Chairman & Executive Vice Chairman of Strategic Development Comp: $167.92kMr. David Jin (Age 33)CFO & Head of Corporate Development Comp: $976.96kDr. George C. Avgerinos (Age 70)Senior Vice President of Biologics Operations Comp: $386.49kMr. Samuel BerryGeneral Counsel & Corporate SecretaryKey CompetitorsChimerixNASDAQ:CMRXscPharmaceuticalsNASDAQ:SCPHRigel PharmaceuticalsNASDAQ:RIGLAchieve Life SciencesNASDAQ:ACHVAgenusNASDAQ:AGENView All CompetitorsInsiders & Institutions180 Wealth Advisors LLCBought 62,350 shares on 7/17/2024Ownership: 0.305%Lindsay A Md RosenwaldBought 5,000 shares on 7/11/2024Total: $37,400.00 ($7.48/share)David JinBought 500 shares on 7/10/2024Total: $3,750.00 ($7.50/share)Lindsay A Md RosenwaldBought 5,000 shares on 7/8/2024Total: $36,750.00 ($7.35/share)Lindsay A Md RosenwaldBought 20,000 shares on 6/28/2024Total: $32,800.00 ($1.64/share)View All Insider TransactionsView All Institutional Transactions FBIO Stock Analysis - Frequently Asked Questions How have FBIO shares performed this year? Fortress Biotech's stock was trading at $3.01 at the beginning of the year. Since then, FBIO shares have decreased by 25.2% and is now trading at $2.25. View the best growth stocks for 2024 here. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) released its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($2.03) by $1.00. The biopharmaceutical company had revenue of $13.03 million for the quarter, compared to analysts' expectations of $14.33 million. When did Fortress Biotech's stock split? Fortress Biotech's stock reverse split on Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Fortress Biotech's major shareholders? Top institutional shareholders of Fortress Biotech include 180 Wealth Advisors LLC (0.31%). Insiders that own company stock include Lindsay A Md Rosenwald, Dov Klein and David Jin. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX) and Vaxart (VXRT). This page (NASDAQ:FBIO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortress Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.